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1 Introduction 
Parkinson’s disease (PD) is a neurodegenerative movement disorder distinguished by 
resting tremor, bradykinesia, rigidity, postural instability and gait disturbances. Non-motor 
symptoms including dysfunction of the autonomic nervous system, neuropsychiatric 
changes, sensory and sleep disturbances are also common. PD may be diagnosed at any age 
but is most common in aged populations - affecting approximately 1% of individuals over 
60 years of age and rising to approximately 4% in age groups above 85 years of age (de Lau 
and Breteler, 2006; Van Den Eeden et al., 2003). It has become apparent that differential 
subgroups may be categorised by age of onset, dominant symptoms and progression. Two 
key subsets include late- and early-onset PD. Late-onset PD is typically identified in 
individuals over the age of 70 and is characterised by postural imbalance and gait 
impairment with accompanying rigidity and akinesia. Early-onset PD is typified by a 
dominant tremor and slow progression in motor decline, and is primarily identified in 
individuals less than 50 years of age (Lewis et al., 2005; Selikhova et al., 2009).  
The lead pathological identifier of PD is moderate to severe dopaminergic neuronal loss 
within the substantia nigra pars compacta with accompanying Lewy pathology in surviving 
neurons (Daniel and Lees, 1993; Dickson et al., 2009; Gelb et al., 1999). It is thought that the 
combination of Lewy pathology and dopaminergic cell loss in PD leads to striatal dopamine 
depletion, and this accounts for the motor symptoms (Obeso et al., 2008). Earlier diagnosis 
of PD is important as motor symptoms do not become apparent until approximately 60% of 
dopaminergic neurons are lost (Fearnley and Lees, 1991; Pakkenberg et al., 1991).  
Current treatments are available to manage the symptoms of PD. Medications such as the 
dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) and inhibitors of dopamine 
metabolism are used to supplement the reduced dopamine level. Deep brain stimulation is 
an alternative treatment. The patient undergoes surgery to implant an electrical stimulation 
device into the affected region of the basal ganglia. The electrical impulses generated by the 
device interfere with the abnormal signals that are causing the tremor, thereby alleviating 
some of the symptoms of the disease (reviewed in (Hurelbrink and Lewis, 2010)). To 
identify treatments that address or arrest the progressive nature of PD, an understanding of 
the molecular mechanisms responsible for the loss of nigrostriatal dopaminergic neurons 
and associated Lewy pathology must be delineated.  
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The aetiology of the majority of PD cases remain unknown, however, gene mutations in 
familial forms of PD account for up to 10% of cases. Over 15 PD loci have been reported and 
greater than 10 genes have been identified (reviewed in (Shulman et al., 2010)). Mutations in 
alpha-synuclein and LRRK2 are the predominant cause of autosomal dominant PD, while 
mutations in parkin and PINK1 cause autosomal recessive PD. Several genome wide 
association studies using large idiopathic PD cohorts have demonstrated an unequivocal 
role for common genetic variation in familial PD genes in the aetiology of idiopathic PD, 
and identified new genetic players including microtubule associated protein tau in sporadic 
disease aetiology (Satake et al., 2009; Simon-Sanchez et al., 2009). 
Mutations in PARK2 (parkin) account for 50% of all familial early-onset PD cases, at least 
20% of young-onset sporadic PD and also contribute to late onset sporadic disease (Foroud 
et al., 2003; Lucking et al., 2000; Mata et al., 2004). Parkin encodes a 465 amino acid multi-
domain protein with homology to a class of enzymes termed E3 ubiquitin-protein ligases 
that function in the ubiquitin proteasome system (UPS) (Shimura et al., 2000). The UPS is the 
predominant cellular pathway for the turnover of misfolded and short-lived intracellular 
proteins (Ciechanover et al., 2000). Parkin mediates the formation of a lysine-48 
polyubiquitin chain linked to the target protein, which functions as a signal for degradation 
by the proteasome. Parkin is also capable of alternative modes of ubiquitination including 
monoubiquitination and lysine-63 polyubiquitination, which appear to function in 
signalling and autophagy, respectively (Chew et al., 2011; Olzmann and Chin, 2008).  
The pathological hallmark of many neurodegenerative diseases is the accumulation of 
proteins in aggregates/inclusions. There is very little information about the neuropathology 
observed in the brains of individuals with parkin-proven PD as only a seven cases have gone 
to autopsy. These cases displayed variable degree of cell loss in the substantia nigra pars 
compacta, and in some cases the locus coeruleus. Several cases displayed evidence of gliosis 
and astrocytosis. With the exception of two cases, Lewy pathology was not identified. 
Evidence of other types of protein aggregation including neurofibrillary tangles, alpha-
synuclein-positive dendritic inclusions and tau accumulation were evident to varying 
degrees (reviewed in (Cookson et al., 2008)). As Lewy pathology is often cited as a 
significant pathological difference between idiopathic and parkin-proven PD some have 
hypothesised that parkin may play an integral role in Lewy formation (von Coelln et al., 
2006). However, due to the small number of autopsies and the limitations of studying end 
stage disease tissues, animal and cell models provide a more detailed mechanistic 
understanding of parkin-mediated PD and the contribution of parkin to idiopathic PD.  
A number of animal and cellular models of parkin dysfunction have been described. Parkin 
knockout flies demonstrated a reduced lifespan, muscle degeneration mitochondrial 
abnormalities, sensitivity to oxidative stress and male infertility (Greene et al., 2003; Pesah et 
al., 2004). While the first reports suggested parkin deficient drosophila did not have 
significant loss of dopaminergic neurons, a subsequent study utilising more sensitive 
analytical techniques indicated a reduction in the number of a subtype of dopaminergic 
neurons (Whitworth et al., 2005). Park2 knockout mice did not appear to display extensive 
behavioural or dopaminergic abnormalities. As such the utility of such models to evaluate 
new pharmaceutical agents is unclear. A number of independent parkin deficient mouse 
models have now been generated. This review will outline the insights provided and look 
ahead to how Park2 knockout mice may help to better understand parkin-mediated PD and 
by extension idiopathic PD. 
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2. Parkin mouse models 
To date, eleven models of parkin dysfunction have been reported, seven of which are 
independently generated Park2 knockout models. Studies on these mice will provide the 
basis of the discussion within. Models noted that are outside the scope of this paper include 
the quaking viable mouse which is a knockout of parkin and PArkin Co-Regulated Gene with 
dysregulation of quaking gene (Lockhart et al., 2004; Lorenzetti et al., 2004;), a recently 
identified spontaneous CH3-Park2E398Q mutant (Ramsey and Giasson, 2010), a model of 
transgenic overexpression of a parkin truncated mutant (Lu et al., 2009) and a model of 
overexpression of wildtype parkin (Yoshida et al., 2010).  
The majority of parkin-proven PD cases are the result of large genomic alterations (deletion, 
duplication or inversion) that affect one or more exons. PARK2 spans an exaggerated 
genomic interval of approximately 1.4 Mb due to super-expanded introns and is located in a 
region of genomic instability (Denison et al., 2003; Palumbo et al., 2010). Several mouse 
models were generated to replicate known deletions that affect a single exon. Exons targeted 
in the Park2 knockout models were exon 2, exon 3 or exon 7, which are predicted to result in 
a peptide/protein of 4aa, 57aa or 243aa truncated, respectively (Table 1). This suggests that 
parkin function would be abrogated in all of these models in the event translation occurs. 
Consistent with loss of function, immunoreactivity corresponding to full length parkin 
could not be detected in any of the knockout mice lines (Table 1 for references). 
2.1 Behavioural characteristics 
PD is a progressive adult onset neurodegenerative disorder, therefore, it would be 
anticipated that disease associated mutations within animal models would replicate this 
feature. For this reason it is important to consider mouse to human age equivalents. It is 
generally considered that between the ages of 3-6 months mice have finished development, 
the rapid maturational growth of most biological processes and structures, but are not 
affected by senescence. These mice are considered to represent ‘mature adults’ equivalent to 
a 20-30 year old human. Changes in senescence can be detected in some but not all mice 
between the ages of 10-15 months, which is considered ‘middle age’ and corresponds to 38-
47 years in humans. Senescence markers can be detected in almost all ‘old’ mice between 18-
24 months of age and these represent approximately 56-69 years in humans. Although for 
each inbred strain it varies, the average life span (50% survivorship) of a laboratory mouse is 
28 months and the upper limit near 36 months, considered the equivalent of approximately 
78 and 94 human years, respectively (Harrison, 2011).  
Park2 knockout mice appear to develop normally, have normal general motor function and do 
not show any obvious clinical phenotype or behavioural abnormality. In one study, Kaplan-
Meier survival analysis using the Park2tm1Roo knockout model suggested an increase in 
mortality, which is consistent with data from PD patients’ pre-L-DOPA therapy (Rodriguez-
Navarro et al., 2007). However, in another study using the Park2tm1Roo knockout model on a 
different background a difference in survival was not found (Guerrero et al., 2008). A 
reduction in body weight was identified in three lines but was not replicated in three other 
lines (Table 2) (Itier et al., 2003; Oyama et al., 2010; Palacino et al., 2004; Perez and Palmiter, 
2005; Von Coelln et al., 2004; Zhu et al., 2007). In addition, a reduced body temperature was 
detected in Park2tm1Roo knockout mice but was not replicated in the Park2tm1Rpa knockout line. 
The findings for adhesive-removal tests and acoustic-startle were also conflicting (Goldberg et 
al., 2003; Itier et al., 2003; Perez and Palmiter, 2005; Von Coelln et al., 2004).  
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B6;129S2-Park2tm1Roo (Itier et al., 2003)1 
Partial replacement of exon 3 with PGK-NeoR cassette resulting in a truncated protein. If 
exon 3 is skipped, the predicted result is a frame shift after parkin amino acid 57 with 
the addition of 49 novel amino acids. 
B6;129S4-Park2tm1Shn (Goldberg et al., 2003) 
Partial replacement of exon 3 with in frame insertion of EGFP followed by PGK-NeoR 
cassette resulting in a truncated protein consisting of the first 95 amino acids of parkin 
followed by EGFP (expression of EGFP protein was not detected). If exon 3 skipping 
occurs, the predicted result is a frameshift after parkin amino acid 57 with the addition 
of 49 novel amino acids.  
B6;129S7/S4-Park2tm1Tmd (Von Coelln et al., 2004)2
Cre-mediated deletion of exon 7 resulting in a frameshift after parkin amino acid 243 
with the addition of 8 novel amino acids. 
B6;129S4-Park2tm1Rpa (Perez and Palmiter, 2005)1 
Complete replacement of exon 2 with Polr2a-NeoR cassette. If exon 2 is skipped, the 
predicted result would be a change in the reading frame producing a 4-aa peptide. 
B6;CBA-Park2tm1Hn (Sato et al., 2006)3 
Partial replacement of exon 2 with in frame insertion of tauGFP fusion protein followed 
by MC1-NeoR cassette to produce tauGFP driven by the parkin promoter (expression of 
tauGFP protein was not detected). If exon 2 skipping occurs, the predicted result would 
be a change in the reading frame producing a 4-aa peptide.  
B6;129P2-Park2tm1Oga(Kitao et al., 2007) 
Complete replacement of exon 3 with PGK-NeoR cassette. If exon 3 is skipped, the 
predicted result is a frame shift after parkin amino acid 57 with the addition of 49 novel 
amino acids. 
B6;129S1/X1-Park2tm1Ccs (Stichel et al., 2007) 
Complete replacement of exon 3 with a NeoR cassette. If exon 3 is skipped, the predicted 
result is a frame shift after parkin amino acid 57 with the addition of 49 novel amino acids. 
Table 1. Park2 knockout mouse models 
Nomenclature guidelines for naming genetically modified mouse strains were followed. 
Information regarding the genetic background of the mouse strain was extracted from the 
embryonic stem cell line strain and strain used in initial chimeric breeding. Only the first 
reported mouse strain is indicated, mutant alleles may have subsequently been bred to other 
strains or isogenicity for subsequent publications. 1Also reported the allele on 129 isogenic 
background but unless indicated experiments were performed on a mixed background. 
2Strain information was obtained from Perez and Palmiter (2005) Supplementary Table 3. 3A 
laboratory code for Nobutaka Hattori, the corresponding author of the publication by Sato 
et al., (2006) could not be identified with the Institute for Laboratory Animal Research 
(ILAR) therefore his initials (Hn) were used. This is only for the purposes of differentiating 
these strains in this chapter and does not represent the true allele designation. 
It was anticipated that parkin-deficient mouse models would display motor defects, which 
would validate their suitability for PD research. Initial experiments indicated that only 
Park2tm1Roo knockout line showed a basal reduction in locomotion (Table 3) (Itier et al., 2003). 
However, when investigated in the same line at 24 months, only a non-significant tendency 
for reduced locomotion was reported (Rodriguez-Navarro et al., 2007). The Park2 knockout 
lines did not show significant deficits on the rotarod, which is used to measure balance,  
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 Body weight Body temperature Adhesive-removal Acoustic-startle 
Park2tm1Roo ↓ 1-16 ↓ 4     
Park2tm1Shn ↓ 1-12   ↓3 2-7   
Park2tm1Tmd − NA     ↓ 9 
Park2tm1Rpa −1 3-24 − 3, 22 − 19 −2 12-15 
Park2tm1Hn         
Park2tm1Oga ↓ NA       
Park2tm1Ccs − 6, 18       
Table 2. General behavioural attributes of Park2 knockout mice 
Attributes investigated in two or more Park2 knockout models. Park2 knockout showed no 
difference (-) or a significant difference compared to wildtype (decreased = ↓, increased = ↑). 
The age(s) of mice (in months) is indicated, if unreported it is shown as not available (NA). 
Gray cells indicate that attribute has not been reported. 1Decrease in weight was identified 
at 6 months of age in the B6:129S4 background but was not reproduced in the 129S4 
background. 2An increased sensitivity was detected in the B6:129S4 background but was not 
reproduced in the 129S4 background. 3A significant decrease was not identified at 18 
months. The table should be used as a guide only as methodology and analysis varies for 
each model. 
 
  
Locomotion 
Amphetamine 
response 
Rotarod Balance-beam Pole Test 
Park2tm1Roo ↓ 6 ↓ 6       
Park2tm1Shn − 6-18   − 6-18 ↓ 2-18   
Park2tm1Tmd − 18   − 3-24     
Park2tm1Rpa −1 3-22 − 3 −3 3-18 − 19 ↓ 6, 18 
Park2tm1Hn − 12 − 12 − 12     
Park2tm1Oga     − 3-12   − 3-12 
Park2tm1Ccs − 6-21 ↓2 3 − 6-24     
Table 3. Motor function of Park2 knockout mice. 
Attributes investigated in two or more Park2 knockout models. Park2 knockout showed no 
difference (-) or a significant difference compared to wildtype (decreased = ↓, increased = ↑). 
The age(s) of mice (in months) is indicated. Gray cells indicate that attribute has not been 
reported. 1Park2tm1Rpa knockout mice exhibited greater locomotor activity specifically during 
the second dark cycle at 12 months only. 2Reported as a lack of amphetamine to induce 
thigmotaxic behaviour. 3Park2tm1Rpa knockout mice were more likely to grip the rotarod at 6 
months. The table should be used as a guide only as methodology and analysis varies for 
each model. 
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coordination, physical condition, and motor-planning (Goldberg et al., 2003; Oyama et al., 
2010; Perez and Palmiter, 2005; Sato et al., 2006; Von Coelln et al., 2004; Zhu et al., 2007). 
Two of the Park2 knockout models appeared to have a reduced response to amphetamine, 
which increases the amount of dopamine in the synaptic cleft and enhances the response of 
post-synaptic neurons, whereas another two did not (Itier et al., 2003; Perez and Palmiter, 
2005; Sato et al., 2006; Zhu et al., 2007). Furthermore, alternative results were reported for 
motor co-ordination determined by the balance beam test and the pole test (Goldberg et al., 
2003; Oyama et al., 2010; Perez and Palmiter, 2005).  
Cognitive function has been investigated in three of the Park2 knockout lines (Table 4). Two 
of the models displayed a reduction in exploratory behaviour which was suggestive of an 
increased anxiety (Itier et al., 2003; Zhu et al., 2007). However, in other tests of cognition, 
including light/dark exploration and T-maze alteration the finding varied depending on the 
Park2 knockout model analysed (Itier et al., 2003; Perez and Palmiter, 2005; Zhu et al., 2007).  
For the most part, based on the aforementioned investigations of the behavioural attributes 
of the Park2 knockout mouse lines it would appear that parkin deficiency does not cause a 
PD-like phenotype in mice. The discrepancies reported for the Park2 knockout lines may be 
attributable to the genetic background of the mouse strain harbouring the mutant allele 
(discussed in (Perez and Palmiter, 2005)). The relative inability to identify a significant 
difference from wildtype for a number of the attributes investigated may be because the 
effect of parkin deficiency is very subtle and the experimental approach lacks the required 
sensitivity. As PD is a progressive disorder, an alternative explanation may be the age of 
Park2 knockout model when the attribute was investigated. For example, 18 month old 
Park2tm1Roo knockout mice showed a significant decrease in the length of their hind limb 
stride, and at 24 months a number of motor and non-motor irregularities were apparent in 
the Park2tm1Roo knockout line that were suggested to parallel symptoms observed in PD 
sufferers (Rodriguez-Navarro et al., 2007). Further investigation when parkin deficiency is 
combined with old age in the Park2 knockout models is required to address this issue. 
 
  
Refuse to 
perform tests 
T-maze 
alternation 
Exploratory 
behaviour 
Light ⁄dark 
exploration 
Morris water 
maze 
Park2tm1Roo ↓ 15 ↓ 4 ↓ 6       
Park2tm1Shn                
Park2tm1Tmd                
Park2tm1Rpa − 3-22 − 12-20    − 12,18 − 18 
Park2tm1Hn                
Park2tm1Oga                
Park2tm1Ccs       ↓ 3 ↓ 3 ↑ NA 
Table 4. Cognitive-related behaviour in Park2 knockout mice. 
Attributes investigated in two or more Park2 knockout models. Park2 knockout showed no 
difference (-) or a significant difference compared to wildtype (decreased = ↓, increased = ↑). 
The age(s) of mice (in months) is indicated, if age was unreported it is shown as not 
available (NA). Gray cells indicate that attribute has not been reported. The table should be 
used as a guide only as methodology and analysis varies for each model. 
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2.2 Pathology 
The pathological hallmark of PD is the loss of dopaminergic neurons within the substantia 
nigra and Lewy pathology. Other regions may also display loss of neurons and/or Lewy 
pathology, including the locus ceruleus, the hypothalamus and some regions of the cortex 
(Halliday and McCann, 2010). The cell body of dopaminergic neurons are predominantly 
localised to three regions of the brain: the substantia nigra pars compacta, the ventral 
tegmental area and the hypothalamus. These neurons project into the putamen to form the 
nigrostriatal dopaminergic system, the ventral striatum or the cortex to form the mesolimbic 
or the mesocortical dopaminergic pathways, and the pituitary gland to form the 
tuberoinfundibular pathway, respectively. In contrast, the largest population of 
noradrenergic neurons is found in the locus ceruleus, and these project to most central 
nervous system areas (Grimm et al., 2004).  
The number and morphology of tyrosine hydroxylase staining neurons in the substantia nigra 
of Park2 knockout mice was not found to be remarkably different from wildtype mice (Table 
5). However, in the Park2tm1Roo knockout line age was an important factor influencing loss of 
dopaminergic neurons. When examined at 2 or 15 months there was no difference in the  
 
  
Morphology of tyrosine hydroxylase 
staining neurons 
Number of tyrosine hydroxylase 
staining neurons 
Park2tm1Roo 
− 2, 15 − 2, 15 ↓1 18, 24 
C, BS, H, SN, ST SN 
Park2tm1Shn 
− NA − 12-24 
LC, SN, ST SN 
Park2tm1Tmd 
− 18 − 12-18 ↓2 2,12-18 
SN, ST SN LC 
Park2tm1Rpa 
− NA − NA 
SN SN 
Park2tm1Hn 
− 3 − 3 
SN LC, SN 
Park2tm1Oga 
  
  
− 26 
SN 
Park2tm1Ccs 
− 6-18 − 6-18 
LC, SN, ST LC, SN  
Table 5. Catecholaminergic neuron pathology in Park2 knockout mice. 
The morphology and number of catecholaminergic neurons in Park2 knockout mice were 
identified by staining with anti-tyrosine hydroxylase antibody. Park2 knockout showed no 
difference (-) or a significant difference compared to wildtype (decreased = ↓, increased = ↑) 
The age(s) of mice (in months) is indicated, if unreported it is shown as not available (NA). 
Gray cells indicate that attribute has not been reported. Brain stem (BS), cerebellum (C), 
locus ceruleus (LC), hippocampus (H), substantia nigra (SN), striatum (ST). 1Significant 
reduction in the number of tyrosine hydroxylase staining neurons at 18 month was only 
identified in female Park2tm1Roo knockout mice. 2Phenotype shows reduced penetrance, ~30% 
of Park2tm1Tmd knockout do not show a significant reduction in the number of tyrosine 
hydroxylase staining neurons in the LC. The table should be used as a guide only as 
methodology and analysis varies for each model. 
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number of dopaminergic neurons in the substantia nigra, but when investigated at 24 months 
a loss of ~35% of neurons was detected (Itier et al., 2003; Rodriguez-Navarro et al., 2007). In 
addition, a significant loss of tyrosine hydroxylase reactivity was demonstrable at 18 months 
in females but not males mice (Rodriguez-Navarro et al., 2008). Notably, in two other models 
examined at or above 24 months no significant loss of dopamineric neurons in the substantia 
nigra was reported (Goldberg et al., 2003; Kitao et al., 2007). Alternatively, in ~70% of 
Park2tm1Tmd knockout mice there was significant reduction in the number of catecholaminergic 
neurons in the locus coeruleus. Such pathology was present at 2 months of age, suggesting 
dysfunctional development of catecholaminergic neurons in the locus ceruleus (Von Coelln et 
al., 2004). As ~30% Park2tm1Tmd knockout mice showed no significant decrease, it is indicative of 
reduced penetrance and suggests other factors must also influence the trait.  
It is generally considered that parkin deletion alone in humans is sufficient to cause PD with 
the onset of symptoms typically earlier than observed for idiopathic PD. The analyses 
summarised in Tables 2 to 5 suggests mouse models of parkin deficiency do not replicate this 
phenotype. However, some of the Park2 knockout models display subtle behavioural and 
pathological phenotypes that parallel PD. Therefore, parkin deficiency in the mouse may 
alter pathways common to human pathogenesis but for as yet unknown reasons do not 
cause a pronounced PD-like phenotype. Observations reported suggest that the mechanistic 
pathways in which parkin functions are conserved between the human and mouse, and 
Park2 knockout mice may be a useful model to further refine the function of parkin and its 
role in disease pathogenesis.  
2.3 Neurochemistry 
It is hypothesised that dysfunction in dopamine metabolism may precede loss of 
dopaminergic neurons and represent a presymptomatic disease state. This is supported by 
studies of dopamine metabolism using positron emission tomography in both parkin-proven 
and idiopathic Parkinson’s disease, and unaffected individuals with heterozygous 
mutations in Parkin and PINK1 (Guo et al., 2010; Sioka et al., 2010; Tang et al., 2010). The 
biosynthetic pathway for dopamine production in catecholaminergic neurons is the 
sequential conversion of phenylalanine to tyrosine, dihydroxyphenylalanine (L-DOPA) and 
dopamine. In dopaminergic neurons the synthesis of dopamine is the final product of the 
process whereas in noradrenergic neurons dopamine may be further modified to 
norepinephrine (Daubner et al., 2011). Within dopaminergic neurons, newly synthesised 
cytoplasmic dopamine is translocated by vesicular monoamine transporter 2 (VMAT2) into 
vesicles for storage until synaptic release. Synaptic dopamine interacts with D1 and D2 
receptors on postsynaptic neurons in the striatum, which mediate the direct and indirect 
dopaminergic pathways, respectively. Within the substantia nigra and the basal ganglia 
synaptic dopamine is inactivated primarily via reuptake by the dopamine transporter (DAT) 
on presynaptic neurons. Intracellular dopamine is then sequestered in vesicles via VMAT 
for re-use or converted by monoamine oxidase (MAO) to 3,4-dihydroxyphenylacetic acid 
(DOPAC) for degradation. DOPAC then diffuses out of the nerve terminal and into the 
extracellular space, where it can be transformed into the more stable metabolite 
homovanillic acid (HVA) via catechol-O-methyltransferase (COMT). To a lesser extent, 
extracellular dopamine can be metabolised without reuptake into presynaptic neurons. In 
this process, extracellular dopamine is converted to 3-methoxytyramine (3-MT) by COMT 
then to HVA by MAO (reviewed in (Standaert and Galanter, 2007)).  
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Investigation of the levels of dopamine and its metabolites DOPAC and HVA in the 
striatum of the Park2 knockout lines did not reveal significant alterations (Table 6) (Itier et 
al., 2003; Oyama et al., 2010; Palacino et al., 2004; Perez and Palmiter, 2005; Von Coelln et al., 
2004). The notable exception was the increase in HVA in the Park2tm1Ccs model (Zhu et al., 
2007). In addition, in a later study, a significant increase in DOPAC and HVA in the striatum 
at 3 months old Park2tm1Roo knockout mice was reported (omitted from table) (Menendez et 
al., 2006). This may be reflective of an increase dopamine metabolism. Likewise, an increase 
in the ratio of DOPAC to dopamine or 3-MT was identified in the striatum of the Park2tm1Roo 
knockout line, perhaps indicative of increased intracellular dopamine metabolism via MAO 
as opposed to extracellular metabolism via COMT (Itier et al., 2003). Although no significant 
difference of total dopamine levels were identified in the striatum of the Park2tm1Shn 
knockout model, the amount of extracellular dopamine in this region was significantly 
increased. In addition, dopamine reuptake was unaltered, which suggests that the increased 
extracellular dopamine was due to increased release of dopamine from presynaptic 
dopaminergic neurons (Goldberg et al., 2003). In contrast, in the striatum of the Park2tm1Hn 
knockout model a reduction in dopamine synthesis and an increase in D1 and D2 receptor  
 
 Dopamine DOPAC HVA Noradrenaline 
Park2tm1Roo 
− 11 ↑ 11 − 11 ↑ 11 − 11 − 11 
BS, D, ST L BS, D, ST L 
BS, D, L, 
ST 
BS, D, L, ST 
Park2tm1Shn 
− 6-24 − 6-24 
  
    
ST ST     
Park2tm1Tmd 
− 18 − 18 − 18 − 18 ↓ 18 
ST ST ST 
BS, C, CC, 
D, H, PC 
OB, SC 
Park2tm1Rpa 
− 22 − 22 − 22 − 18-22 
ST MB, ST ST OB, SC, ST 
Park2tm1Hn 
↑ 12 − 12 − 12 − 12     
MB ST MB, ST MB, ST     
Park2tm1Oga 
− 3-12 − 3-12 − 3-12   
  
  
  ST ST ST 
Park2tm1Ccs 
− NA − NA ↑ NA   
  
  
  ST ST ST 
Table 6. Neurochemical analysis of Park2 Knockout mice 
The level of dopamine, its metabolites 3,4-Dihydroxyphenylacetic acid (DOPAC) and 
homovanillic acid (HVA) and its derivate noradrenaline were analysed. Park2 knockout 
showed no difference (-) or a significant difference compared to wildtype (decreased = ↓, 
increased = ↑). The age(s) of mice (in months) is indicated, if unreported it is shown as not 
available (NA). Gray cells indicate that attribute has not been reported. Brain stem (BS), 
cerebral cortex (CC), cerebellum (C), diencephalon (D), hippocampus (H), limbic region (L), 
olfactory bulb (OB), midbrain (MB), prefrontal cortex (PC), spinal cord (SC), substantia nigra 
(SN), striatum (ST). The table should be used as a guide only as methodology and analysis 
varies for each model. 
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binding was detected using receptor specific antagonists. This suggests decline in striatal 
dopamine release may result in decreased synaptic dopamine (Sato et al., 2006). Similar 
analysis in the Park2tm1Shn knockout line however, did not indicate an alteration in the 
amount of D1 or D2 receptor binding in the striatum (Goldberg et al., 2003; Kitada et al., 
2009a). In the Park2tm1Hn line the binding index of DAT and VMAT was unchanged and 
suggests that the levels of these proteins are not altered (Sato et al., 2006). Likewise, the level 
of DAT in the Park2tm1Shn knockout mice, measured using radiolabeled dopamine uptake, 
suggested that DAT levels were not altered (Kitada et al., 2009a). However, a reduction of 
the DAT and VMAT protein levels were identified in the Park2tm1Roo line (Itier et al., 2003). 
Alterations in dopamine metabolism were also found in other brain regions. An increase in 
the level of dopamine and DOPAC was identified in the limbic region from Park2tm1Roo 
knockout mice, and an increase in dopamine but not DOPAC was identified in the 
midbrain, which includes the limbic region, from the Park2tm1Hn knockout line (Itier et al., 
2003; Sato et al., 2006). In addition, in the Park2tm1Tmd knockout model, which showed loss of 
noradrenergic neurons within the locus coeruleus, a significant reduction in the dopamine 
derivative norepinephrine was identified in two regions that are innervated by the locus 
ceruleus, the olfactory bulb and the spinal cord (Von Coelln et al., 2004). Although a number 
of discrepancies related to dopamine metabolism are evident between the different Park2 
knockout models, collectively these analyses have suggested parkin may play a role in the 
presynaptic release of dopamine. The loss of parkin function may alter dopamine release, 
potentially by affecting vesicular packaging. Furthermore, they suggest that alterations in 
presynaptic dopamine function are evident prior to the development of PD-associated 
pathology.  
2.4 Synaptic transmission 
Deficits in dopamine-related synaptic transmission have been identified in parkin-mediated 
PD (Guo et al., 2010). Studies in a number of the Park2 knockout lines suggest the 
presynaptic dopamine transmission is perturbed. In the Park2tm1Shn knockout line, the 
evoked dopamine signal of medium spiny-neurons, the major class of striatal neurons 
whose excitability is influenced by dopamine levels, was reduced and could not be restored 
with DAT inhibition, suggesting dopamine re-uptake was not affected (Goldberg et al., 
2003). Long term depression (LTD), which is activity-dependent reduction in the efficacy of 
neuronal synapses that lasts for an extended period, was also found to also be dysfunctional 
in these neurons. LTD could be restored by increasing synaptic dopamine with 
amphetamine but not by inhibition of dopamine re-uptake by antagonism of DAT. In 
addition, simultaneous antagonism of both D1 and D2 receptors, but not individual receptor 
antagonism, was required to restore LTD, and L-DOPA treatment was also effective. 
Furthermore, using primary dissociated adrenal chromaffin cells, which enable real time 
analysis of catecholamine release from single vesicles, exocytosis was found to be reduced 
(Kitada et al., 2009a). These observations suggest neurons from Park2tm1Shn knockout have an 
intrinsic impairment in synaptic transmission that may result from defective presynaptic 
dopamine release. 
The amplitude and half-life of evoked dopamine overflow was reduced in nigrostriatal 
fibers of the medial forebrain bundle of Park2tm1Oga knockout mice. These are reflective of 
competing mechanisms of synaptic release and re-uptake, indicating that these mice also 
have alterations in dopamine synaptic transmission. Furthermore, a progressive age related 
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reduction in facilitation of these neurons was identified, which may be reflective of 
presymptomatic age-related changes (Oyama et al., 2010). The synaptic strength of 
hippocampal neurons from Park2tm1Rpa line was significantly weaker in mice carrying one 
Park2tm1Rpa mutant allele but not two mutant alleles. Hemizygous mice consistently showed 
reduced pair-pulse ratio whereas Park2tm1Rpa knockout mice were only affected under small 
inter-stimulus ranges. Changes in pulse-pair ratio are consistent with presynaptic 
abnormalities, suggesting that in Park2tm1Rpa mouse line parkin deficiency also affects 
presynaptic process.  
Long term potentiation (LTP) is a long-lasting enhancement in signal transmission between 
two neurons that results from stimulating them synchronously, and is considered one of the 
major cellular mechanisms that underlies learning and memory. In the Park2tm1Rpa knockout 
line, the LTP of 24 month old, but not 2 month old, appeared to be more robust, which may 
suggest that there is an absence of normal age related decline in the hippocampus of these 
mice (Hanson et al., 2010). In contrast, LTP was unchanged in the hippocampus of 
Park2tm1Roo knockout line of a similar age (Itier et al., 2003). Furthermore, LTP was also 
unaltered in the hippocampus of Park2tm1Shn knockout mice but could not be induced in 
striatal medium spiny neurons (Kitada et al., 2009a). Studies carried out to date on Park2 
knockout mice suggest that these mice have presynaptic abnormalities affecting dopamine 
function, which may be differentially modulated by the homozygous or heterozygous state 
of the mutant allele, cellular and regional specificity and/or age. 
2.5 Neuroinflammation 
Neuroinflammation is the chronic presence of activated microglia and reactive astrocytes, 
and associated mediators of the immune response in the central nervous system (reviewed 
in (Lee et al., 2009)). Postmortem analyses have demonstrated activated glia in both the 
striatum and in the substantia nigra of patients with idiopathic PD and in parkin-proven PD 
(reviewed in (Cookson et al., 2008; Lee et al., 2009)).  
In vivo, Park2tm1Ccs and Park2tm1Roo knockout mice did not appear to have increased astrocytic 
or microglial markers in the substantia nigra, striatum or midbrain (Rodriguez-Navarro et 
al., 2007; Schmidt et al., 2011). However, a significant increase in the number of astrocytes in 
the striatum and the number of microglia in the midbrain occurs with age in the Park2tm1Roo 
mice, independent of parkin deficiency, indicating an age-associated increase in the 
inflammatory environment may contribute to neuronal degeneration (Rodriguez-Navarro et 
al., 2007). In vitro however, alterations of glial populations are evident. Neuronal enriched 
cultures derived from Park2tm1Roo knockout embryos appear to be enriched for microglial and 
glial progenitor cells (Casarejos et al., 2005), and glial cultures appear to have a reduced 
proportion of astrocytes compared to wildtype derived cultures (Solano et al., 2008). 
Furthermore, glial conditioned medium from Park2tm1Roo and Park2tm1Ccs knockout mice were 
found to have reduced neuroprotective capabilities that suggest a reduction in a trophic 
factor production or excretion by astrocytes (Schmidt et al., 2011; Solano et al., 2008).  
Park2tm1Shn knockout mice have been used to investigate if parkin deficiency can affect 
vulnerability to inflammation-mediated dopaminergic degeneration, using sustained low 
dose intraperitoneal injection of lipopolysaccaride (LPS). LPS is a bacterial endotoxin that is 
used as a glial activator for the induction of inflammatory dopaminergic neurodegeneration 
(Dutta et al., 2008). Park2tm1Shn knockout mice showed increased vulnerability to LPS 
treatment and developed fine motor deficits and a loss of dopaminergic neurons (Frank-
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Cannon et al., 2008). This suggests that parkin deficiency selectively increases the 
vulnerability of dopaminergic neurons to the effects of LPS induced inflammatory 
dopaminergic neurodegeneration. Collectively, these studies suggest that there may be 
inherent dysregulation of glial cells in parkin deficiency. Alterations in the function of these 
mediators of neuroinflammation within parkin-proven PD, together with endogenous age 
related changes in the neuroimmune system may play a role in the pathogenesis of PD.  
2.6 Oxidative stress 
Oxidative stress occurs when there is an imbalance between the production of reactive 
oxygen species (ROS) and the ability to rapidly detoxify the reactive intermediates or repair 
the resulting damage to cellular constituents. Markers of oxidative stress are increased in PD 
patients (reviewed in (Tobon-Velasco et al., 2010)), and dopamine metabolism facilitates 
production of ROS (Lotharius and Brundin, 2002). Glutathione (GSH) is a free radical 
scavenger that acts on redox reactive molecules. Both astrocytes and neurons have the 
capacity to synthesis GSH, but astrocytes are known to play an important role in supply of 
GSH and other substrates to neurons. One of the earliest biochemical changes observed in 
PD patients is a decrease in GSH levels. It is thought the decrease in GSH levels may be due 
to increased oxidative stress and recent research suggests that GSH depletion itself may 
have a role in the pathogenesis of PD (reviewed in (Martin and Teismann, 2009)). 
Park2tm1Roo knockout mice aged 2 months were found to have significantly increased GSH in 
the midbrain, striatum and limbic system (Itier et al., 2003; Rodriguez-Navarro et al., 2007). 
However, when GSH levels were investigated in Park2tm1Roo knockout mice aged 24 months, 
the level of GSH in the midbrain was not significantly different from either the 24 month old 
wildtype or 2 month old knockout mice. While GSH levels in the striatum of 24 month 
Park2tm1Roo knockout mice were significantly reduced compared to 2 month old knockout 
mice they were not significantly different to 24 month old wildtype mice. In the limbic 
system of 24 month old Park2tm1Roo knockout mice the level of GSH was significantly 
increased compared to 24 month old wildtype mice. Therefore, regional and age-related 
alterations of GSH are present in the Park2tm1Roo knockout mouse line. Consistent with these 
observations, in vitro age-related studies of alterations in GSH levels have been identified in 
glial cells derived from Park2tm1Roo knockout mice. When knockout glia are cultured for an 
extended period (6-9 months) the intracellular levels of GSH were significantly reduced 
compared to wildtype control glia, whereas knockout glia cultured for a shorter time (1-3 
months) were shown to have a significant increase in the level of intracellular GSH 
compared to wildtype (Solano et al., 2008). However, conditioned media generated from 
glial cultures derived from Park2tm1Roo knockout mice that had been cultured for a shorter 
period had lower levels of GSH and higher levels of hydrogen peroxide, and appeared to be 
less neuroprotective to wildtype neurons than conditioned media from wildtype glial 
cultures (Solano et al., 2008). These observations suggest that although intracellular GSH 
levels are increased in 2 month old Park2tm1Roo knockout, there may be defective exocytosis of 
GSH out of the glia and into the extracellular space. 
Mitochondria are a major source of ROS within cells and mitochondrial dysfunction has 
been robustly implicated with PD. The capacity for electron transport in mitochondria was 
found to be impaired in the Park2tm1Shn and Park2tm1Ccs knockout mice (Palacino et al., 2004; 
Stichel et al., 2007). Dopaminergic neurons in the Park2tm1Rpa and Park2tm1Tmd knockout lines 
do not appear to be more sensitive to the mitochondrial toxin MPTP (Perez et al., 2005; 
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Thomas et al., 2007). However, glial cultures derived from Park2tm1Roo knockout mice 
appeared more sensitive to MPTP (Solano et al., 2008). Furthermore, neuronal cultures 
derived from Park2tm1Roo knockout mice were more sensitive to the mitochondrial toxin 
rotenone. Co-culture of glia from Park2tm1Roo knockout mice with neurons derived from 
wildtype mice increased the sensitivity of wildtype neurons to rotenone (Casarejos et al., 
2006). Furthermore, wildtype neurons exhibited significantly shorter processes and smaller 
neuronal areas when they were co-cultured with Park2tm1Ccs knockout derived astrocytes as 
opposed to wildtype astrocytes (Schmidt et al., 2011). Collectively, this suggests that lack of 
parkin leads to a functional disturbance of neuron-glia interactions, and that 
environmentally induced mitochondrial dysfunction when combined with parkin deficiency 
may be detrimental to dopaminergic neurons and stimulatory of neuroinflammatory 
processes.  
The ultrastructure of mitochondria from Park2tm1Ccs knockout mouse has been investigated in 
both neuronal and glial populations in vivo. Compared to 3 month old mice, neurons in the 
substantia nigra of 12 month old Park2tm1Ccs knockout mice displayed an increased 
proportion of abnormal mitochondria. This age related change was not identified in 
wildtype mice (Stichel et al., 2007). Mitochondria within glial populations of Park2tm1Ccs 
knockout mice were found to exhibit an elevated number of structural deficits that included 
abnormal disintegration, a reduction of mitochondrial cristae and mitochondrial 
enlargement. The proportion of abnormal mitochondria identified in Park2tm1Ccs knockout 
glia depended on both age and glial cell type. Nonetheless, the amount of mitochondrial 
damage was significant at just 16 days of age in all glial cell types, and the mitochondrial 
burden was much greater in glial than neuronal cells (Schmidt et al., 2011). Oxidative stress 
is thought to be a major contributor to the development of PD. Several pathways associated 
with oxidative stress, notably GSH and the mitochondria, may be dysfunctional within 
Park2 knockout mice. Furthermore, it appears that a number of factors including age and 
cell type may mediate the extent of dysfunction associated with lack of parkin.  
2.7 Ubiquitin Proteasome System (UPS) 
Parkin was originally identified as an E3 ubiquitin ligase that functions in the UPS, and a 
number of putative interacting proteins and substrates have subsequently been identified 
(reviewed in (Dawson and Dawson, 2010)). Knockout mice allow the in vivo analysis of 
interacting proteins, substrates and pathway deficits that have been identified in vitro. A 
simple working hypothesis is that if a protein is a substrate of parkin mediated 
ubiquitination and subsequent degradation via the UPS, that protein would be expected to 
accumulate in a Park2 knockout mouse model. A number of groups have investigated some 
of the putative parkin substrates in Park2 knockout mice, but in general very few studies 
have replicated the in vitro results and shown increased levels of putative substrates in vivo.  
Two comprehensive analyses of parkin substrates have been reported using the Park2tm1Tmd 
knockout mice. The steady state level of aminoacyl-tRNA synthetase cofactor (AIMP2) was 
increased in the ventral midbrain/hindbrain of Park2tm1Tmd knockout mice but no alteration 
in the amount of seven other putative parkin substrates, including ǃ-tubulin and ǂ-
synuclein, was identified. An accumulation of AIMP2 in brain tissue from individuals with 
parkin-proven PD was also shown, and AIMP2 was shown to interact with parkin in vitro, 
suggesting that AIMP2 is an authentic substrate of parkin (Ko et al., 2005). AIMP2 is a 
known interacting protein of far upstream element (FUSE)-binding protein 1 (FBP1), 
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promoting its ubiquitination and degradation. Subsequent studies demonstrated that the 
level of FBP1 was increased in the brain stem and cortex of Park2tm1Tmd knockout mice and 
also patients with parkin-proven PD (Ko et al., 2006). In contrast to the results in the ventral 
midbrain/hindbrain of Park2tm1Tmd knockout mice, the level of AIMP2 in the cortex, 
cerebellum, brain stem, and striatum, and the level of FBP1 in the ventral midbrain, 
cerebellum or striatum was not altered (Ko et al., 2006; Ko et al., 2005). This may imply 
functional redundancy for turnover of these proteins in some regions of the brain. However, 
an alternative explanation may be that the rate of new protein synthesis is greater than the 
rate of protein degradation in these regions and so the effect of parkin absence is masked. A 
similar phenomenon was observed with estrogen related receptor (ERR) isoforms and ǂ-
tubulin. The consequence of loss of parkin on accumulation of ERRs and ǂ-tubulin was only 
demonstrated after new protein synthesis was inhibited by treatment with puromycin (Ren 
et al., 2010).  
In general, in vitro studies suggesting a role for parkin in the turnover of putative substrates 
have not been replicated in the different in vivo models. However the extent to which 
investigation has been reported is limited. Such apparent discrepancy between in vitro and 
in vivo models may due in part to experimental methodology. For example, the in vitro data 
suggesting a role for parkin in ubiquitin-proteasome mediated degradation may be an 
artefact of exogenous expression of parkin and putative substrates, or due to specificity of 
the cell type utilised. In addition, there is compelling evidence to suggest that parkin is able 
to function as a multifaceted ubiquitin ligase, capable of modulating alternative forms of 
ubiquitination not associated with ubiquitin-proteasome mediated degradation of proteins.  
2.8 Autophagy 
For a substrate to be recognised by the proteasome it needs to labelled with at least four 
ubiquitin molecules attached via lysine-48 linkage. Most recently, parkin-mediated lysine-63 
polyubiquitylation was shown to be an important mediator of the aggregation and turnover 
of damaged mitochondria via autophagy (Geisler et al., 2010; Narendra et al., 2008; 
Narendra et al., 2010; Suen et al., 2010). Autophagy is the major pathway involved in the 
degradation of long-lived proteins and organelles and has been shown to play an integral 
role in protection against neurodegeneration (Hara et al., 2006; Komatsu et al., 2006). It is 
comprised of three distinct pathways, macroautophagy, microautophagy and chaperone-
mediated autophagy. Macroautophagy (hereafter referred to as autophagy) involves the 
sequestration of organelles and proteins in a double-membrane vesicle, called an 
autophagosome or autophagic vacuole, which subsequently fuses with a lysosome and the 
contents are degraded by lysosomal hydrolases (reviewed in (Klionsky and Emr, 2000)). 
Emerging data suggests that the UPS and autophagy are functionally coupled and inhibition 
of the UPS can result in aggresome formation and elevated autophagy (Pandey et al., 2007). 
Several markers of the autophagic pathway have been shown to be elevated in the 
substantia nigra of PD cases and it has been proposed that Lewy bodies may be the in vivo 
representation of aggresome. It is not yet clear if the elevated numbers of autophagosomes 
identified in PD brains represent increased autophagy induction or impaired completion of 
autophagic degradation (reviewed in (Chu, 2011)). However, the ability of the autophagic 
vacuole to engulf organelles and large protein aggregates suggests upregulation of 
autophagy may represent a therapeutic target for PD (reviewed in ((Arduino et al., 2010; 
Banerjee et al., 2010)). Recent studies have defined a pathway linking parkin and PINK1 to 
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mitophagy, a form of autophagy selective for mitochondria. Depolarisation of mitochondria 
results in the accumulation of parkin at the mitochondrion in a PINK1-dependent manner 
with subsequent degradation via mitophagy (Kawajiri et al., 2010; Narendra et al., 2008; 
Narendra et al., 2010; Vives-Bauza et al., 2010).  
The effect of parkin deficiency on autophagy in Park2 knockout mice has not been 
extensively reported. However, one study has investigated autophagy in neuronal cultures 
derived from Park2tm1Roo knockout mice. Midbrain neuronal cultures derived from Park2tm1Roo 
knockout mice were treated with epoxomicin to partially inhibit the proteasome. Park2tm1Roo 
knockout cultures appeared to be less susceptible to the toxic effects of proteasomal 
inhibition. The autophagic substrate p62 was increased in wildtype neuronal cultures but 
not in Park2tm1Roo knockout neuronal cultures, suggestive of increased autophagic activity. A 
second indicator of autophagic activity is the relative ratio of LC3I and LC3II. LC3 II is 
generated by site specific proteolysis and lipidation of LC3I and serves as a specific marker 
of autophagic activation. In basal conditions, the LC3II/I ratio was unchanged in neuronal 
cultures derived from wildtype mice, but it was significantly increased in cultures from 
derived Park2tm1Roo knockout mice, and this was further potentiated by epoxomicin 
treatment. These observations suggest that neuronal cultures derived from Park2tm1Roo 
knockout mice have increased autophagy and that partial proteasomal inhibition further 
potentiates autophagy in this model (Casarejos et al., 2009). The majority of cell culture 
models have suggested that Parkin regulates mitochondrial degradation through 
autophagy, and an early step in this process is the requirement for PINK1 to recruit Parkin 
to the mitochondria (Vives-Bauza et al., 2010). Therefore, it seems counter intuitive that 
neuronal cultures derived from Park2tm1Roo knockout mice would display increased 
autophagy following proteasomal inhibition. However, a study of neurons taken from rat 
substantia nigra suggested that mitophagy was parkin independent in these cells. It was 
suggested that the difference in neurons may be due to the high dependence of neurons on 
mitochondrial respiration (Van Laar et al., 2011). Much of what is currently understood 
about the potential role of parkin in autophagy is derived from studies in cell culture 
models. However, this is an expanding field in PD research and future studies utilising 
Park2 knockout mice will provide considerable insight into the significance of this role in 
vivo. 
2.9 Trafficking/signalling 
Parkin-mediated ubiquitination has also been suggested to play a role in signal transduction 
and trafficking. Monoubiquitination is associated with the regulation of endocytosis of 
membrane proteins and signalling (Mukhopadhyay and Riezman, 2007). The interaction 
between parkin and PICK1 is an example of this function. PICK1 regulates the trafficking 
and stability of a number of synaptic proteins, including neurotransmitter receptors, 
transporters and ion channels (Madsen et al., 2005). In vitro analysis suggested that parkin 
monoubiquitinated rather than polyubiquitinated PICK1. In neurons derived from 
Park2tm1Roo knockout mice steady-state PICK1 levels were not altered, suggesting turnover of 
the protein is independent of parkin. PICK1 has been shown to interact with the proton-
gated ion channel ASIC2a, and potentiation of ASIC2a currents is suggested to be PICK1 
dependent. Hippocampal neurons from Park2tm1Roo knockout mice show deficits of ASIC2a 
current potentiation, which suggest that monoubiquitination of PICK1 by parkin is required 
for ASIC2a channel function (Joch et al., 2007).  
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The interaction of parkin and the endocytic protein Endophilin A1 provides additional 
evidence that the ubiquitination activity of parkin is not limited to proteasome turnover. 
Endophilin A1 is a protein that is abundant in neural synapses and is involved in formation 
of presynaptic endocytic vesicles. Limited ubiquitination of Endophilin A1 by parkin was 
shown in vitro and Endophilin A1 did not appear to accumulate in synapses from Park2tm1Roo 
knockout mice. In vivo the interaction of the two proteins appears to promote co-localisation 
from the cytosol to the plasma membrane and synaptic vesicle enriched fractions. In 
synaptosome preparations from wildtype mice relocalisation leads to increased ubiquitination 
of synaptic proteins, however, this effect is abrogated in Park2tm1Roo knockout mice (Trempe 
et al., 2009). Further understanding of the functional deficits associated with this loss of 
relocalisation and ubiquitination activity in Park2 knockout mice may shed light on the 
defects in synaptic transmission observed in both Park2 knockout mice and parkin-mediated 
PD.  
2.10 Genetic modification of Park2 knockout mice 
Mutations in the genes parkin, PINK1 and DJ-1 have been associated with familial recessive 
early-onset PD. A number of lines of evidence suggest that these genes may function in a 
common pathway(s) important for mitochondrial function (Geisler et al., 2010; Narendra et 
al., 2010; Thomas et al., 2011). The effect of knockout of all three genes in a single mouse 
model revealed that Park2tm1Shn/Pink1/Dj-1 knockout mice at 24 months of age do not show 
significant dopaminergic degeneration (Kitada et al., 2009b). This may suggest a functional 
redundancy between these genes. An alternative interpretation may be that these genes are 
not essential for neuronal survival, but rather may play a protective role against cellular 
insults. 
A major component of Lewy bodies in PD is alpha-synuclein, which is also genetically 
linked with autosomal dominant PD and sporadic PD (reviewed in (Obeso et al., 2010). The 
effect of parkin deficiency combined with dysregulation of ǂ-synuclein has been reported 
for three Park2 knockout mouse lines. The Park2tm1Tmd knockout mouse was crossed with a 
transgenic mouse overexpressing familial mutant A53T ǂ-synuclein under the control of the 
mouse prion promoter [Tg(PRP-SNCAA53T)]. In this model, parkin deficiency did not appear 
to exacerbate attributes previously recognised in Tg(PRP-SNCAA53T) mice. Likewise, 
Tg(PRP-SNCAA53T) did not potentiate the locus coeruleus degeneration of the Park2tm1Tmd 
knockout line (von Coelln et al., 2006). The Park2tm1Roo knockout mouse was crossed with a 
transgenic mouse overexpressing familial mutant A30P ǂ-synuclein under the control of the 
thymus cell antigen 1 promoter [Tg(THY1-SNCAA30P)]. In contrast to the previous model, 
parkin deficiency appeared to delay the progressive neurodegenerative motor phenotype of 
Tg(THY1-SNCAA30P) mice, and decreased neuritic pathology that is associated with these 
symptoms. Furthermore, co-staining of ubiquitin with phosphorylated ǂ-synuclein positive 
structures was reduced in this model (Fournier et al., 2009). The Park2tm1Ccs knockout mouse 
was crossed with two different mutant ǂ-synuclein lines. Both lines expressed human ǂ-
synuclein carrying two familial mutations, A30P and A53T, under the control of either the 
chicken beta-actin (BA) promoter [Tg(BA-SNCAA30/PA53T)] or the mouse tyrosine 
hydroxylase (TH) promoter [Tg(TH-SNCAA30/PA53T)]. The most prominent feature identified 
in neurons from these mutant mice was an age-related increase in the proportion of 
abnormal mitochondria and a reduction in mitochondrial complex I activity in the 
substantia nigra (Stichel et al., 2007). Collectively, these studies suggest that the effect of 
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parkin deficiency on ǂ-synuclein mediated phenotypes may be independent (von Coelln et 
al., 2006), delayed (Fournier et al., 2009) or enhanced (Stichel et al., 2007). Whether this is 
related to differential attributes of the Park2 knockout mice or the differential regional effects 
of ǂ-synuclein overexpression remains to be investigated.  
The normal age related increase of tau pathology is potentiated in the Park2tm1Roo knockout 
mouse (Rodriguez-Navarro et al., 2007). Tauopathies are neurodegenerative diseases 
principally identified by dementia and Parkinsonism. Idiopathic forms are thought to be 
due to post-translational alteration of tau whereas familiar tauopathies are the result of 
mutations in the gene encoding tau, microtubule associated protein tau (MAPT) (Avila et al., 
2004; Hutton et al., 1998). MAPT has also recently been genetically implicated in sporadic 
PD aetiology (Satake et al., 2009; Simon-Sanchez et al., 2009) and aggregation of tau has 
been shown to be a feature of some cases of parkin-proven PD (reviewed in (Cookson et 
al., 2008).  
The consequence of combining the over-expression of a human 4-repeat tau isoform with 
known familial alterations G2727V, P301L, R406W under the control of human thymus 
cell antigen 1 promoter [Tg(THY1-TauVLW)] with the Park2tm1Roo knockout mouse was 
investigated. Like Park2tm1Roo knockout mice, Tg(THY1-TauVLW) mice have slight 
behavioural and molecular changes that do not manifest in a clinical phenotype. 
However, when combined a number of age-progressive behavioural attributes including 
reduced hind limb length, uncontrolled movements, loss of balance and postural 
abnormalities as well as increased self-injury of the face that is a reflection of compulsive 
long-term grooming, were identified. This was coupled with a significant loss of motor 
neurons, and dopaminergic neurons in the substantia nigra. In addition, tau pathology 
was identified, as was abnormal expression glia in the substantia nigra and the 
hippocampus (Menendez et al., 2006; Rodriguez-Navarro et al., 2008a). Furthermore, 
phosphorylated tau plaques and tangles, as well as endogenous ǃ-amyloid plaques were 
found in the hippocampus. Notably, dietary supplementation with the disaccharide 
trehalose, which is thought to enhance autophagy, was found to ameliorate the severity of 
the symptoms and pathology in this model. (Rodriguez-Navarro et al., 2010). By 
combining parkin deficiency with abnormal tau expression, a number of attributes that 
were modestly perturbed in the single monogenetic mutants were significantly 
dysregulated. This suggests that parkin and tau may be functionally coupled in vivo, and 
their perturbation is capable of eliciting a progressive neurodegenerative phenotype with 
characteristics of both PD and Alzheimer’s disease.  
Alzheimer disease is a degenerative dementia characterised by loss of neurons in the 
cerebral cortex. Pathological features include extracellular amyloid plaques, which are 
composed predominately of ǃ-amyloid, and intracellular neurofibrillary tangles that mainly 
consist of hyperphosphorylated tau. The identification of ǃ-amyloid plaques in the 
Park2tm1Roo/Tg(THY1-TauVLW) mouse led to the investigation of the effect of parkin 
deficiency on ǃ-amyloid expression. The APPswe is a transgenic mouse line that 
overexpresses the ǃ-amyloid precursor protein containing two mutations, K670N and 
M671L, under the control of the prion protein promoter. Parkin deficiency appears to reduce 
the severity of behavioural deficits of APPswe mice including reduced weight gain, 
exploratory activity and working memory. Furthermore, parkin deficiency appears to 
reduce ǃ-amyloid plaque pathology within the cerebral cortex and hippocampus, and in the 
hippocampus the amount of astrogliosis and phosphorylated tau was also reduced. This 
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was coupled with alterations in a number of autophagic markers consistent with induction 
of autophagy (Perucho et al., 2010). 
Therefore, in contrast to the Park2tm1Roo/Tg(THY1-TauVLW) mouse, where combining the two 
mutant alleles appeared to enhanced the disease process, parkin deficiency combined with 
APPswe over-expression can ameliorate a number of pathological characteristics of these 
mice. Consequently, it appears parkin has the potential to be both neuroprotective and a 
neurotoxic to the neurodegenerative process, depending on context. Furthermore, the effect 
of active autophagy when either APPswe or Tg(THY1-TauVLW) were combined with 
Park2tm1Roo knockout appears to be protective. This suggests further investigation into factors 
that enhance autophagy may identify potential treatments for individuals with PD and 
other neurodegenerative disorders.  
3. Discussion 
PD is differentiated from other neurodegenerative disorders by defined motor disturbances 
resulting from the pathological loss of dopaminergic neurons. Seven Park2 knockout models 
have been generated and characterised. In the current context, loss of function of parkin in 
these mouse models does not appear to reproduce a PD-like phenotype that is reflective of 
parkin-proven PD. However, two models showed a significant loss of catecholaminergic 
neurons, one in the substantia nigra and the other in the locus coeruleus. Notably, the extent 
of neuronal loss within the substantia nigra was not equivalent to that associated with the 
onset of symptomatic PD in humans. However, both neurochemical and 
electrophysiological studies have identified disturbances in dopamine pathways in Park2 
knockout mice that are consistent with altered presynaptic release of dopamine. Glial and 
redox dysfunction was also identified, indicating that the capacity to protect neurons against 
cellular insult may be diminished in Park2 knockout mice. Furthermore, mitochondrial 
abnormalities highlight the importance of parkin function in maintaining mitochondrial 
integrity. Accumulation of specific proteins within Park2 knockout mice has confirmed in 
vivo that parkin functions as an E3 ubiquitin ligase in the UPS. The additional role of parkin 
in autophagy and trafficking/signalling pathways are indicative of a broad role in normal 
cellular function. With regard to the involvement of parkin with neurodegeneration the 
most important findings were identified by genetic modification of Park2 knockout mice. 
Park2 knockout mice, when combined with other mutant transgenic models, appeared to 
have the capacity to both exacerbate and ameliorate disease associated characteristics in a 
context dependent manner. Therefore, dysfunction of parkin has the potential to be both 
neuroprotective and neurotoxic.  
The inability of Park2 knockout mice to adequately recapitulate the clinical and pathological 
manifestation of PD is not an isolated observation. Knockout of other PD associated genes 
such as Pink1, α-synuclein and Lrrk2 also fail to produce robust PD-like phenotypes, and the 
results of transgenic overexpression of disease associated genes and mutants vary 
considerably depending on the promoter used to drive expression (reviewed in (Dawson et 
al., 2010)). In addition, a knockin model of a common pathogenic variant of LRRK2 does not 
show evidence of dopaminergic degeneration. However, like Park2 knockout mice these 
Lrrk2 knockin mice appear to have dysregulation of the dopamine system (Tong et al., 2009). 
In addition, a number of other features identified in Park2 knockout mice, including 
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alterations of the neuroimmune system, mitochondrial dysfunction and oxidative stress are 
shared between the models. These observations suggest a commonality to the perturbations 
that occur prior to manifestation of pathogenic phenotypic features.  
An explanation as to why Park2 knockout mice fail, for the most part, to recapitulate the loss 
of dopaminergic neurons that is a feature of human disease may be the short lifespan of the 
species. Aging research carried out in mice indicate that a number of molecular markers of 
aging follow a similar course to that observed in humans, although over a shorter duration. 
(reviewed ((Yuan et al., 2011)). This suggests that at the cellular and systemic level aging 
follows a parallel path in mice and humans. The symptoms of parkin-mediated PD typically 
present before 45 years of age. However, there is considerable disparity in age of onset, 
presentation, progression and response to drug treatment, even for patients within the same 
sibship, with the same mutations (reviewed in (Mata et al., 2004)). Therefore, loss of function 
of parkin alone may not be responsible for dopaminergic neuronal loss in individuals with 
parkin-mediated PD. Three lines of evidence from studies carried out in Park2 knockout mice 
support this notion. 1) A significant loss (35%), of dopaminergic neurons occurs in the 
substantia nigra of the Park2tm1Roo knockout in an age-related progressive manner over the 
duration of the life-span of the mouse, although not to the extent that is observed (~60%) at 
symptom onset in humans. This indicates that parkin deficiency can cause dopaminergic 
neuronal loss in a mouse model. 2) The loss of catecholaminergic neurons in the locus 
coeruleus in the Park2tm1Tmd knockout line shows reduced penetrance. This suggests that 
additional factors mediate this trait. 3) The increased vulnerability of Park2tm1Shn knockout 
mice to loss of dopaminergic neurons in the substantia nigra induced by repeated low-dose 
systemic LPS treatment. This indicates that in this model, although parkin deficiency alone 
was not sufficient to cause dopaminergic neuronal loss, dopaminergic integrity was 
compromised in a neuroinflammatory environment. 
A number of the phenotypic discrepancies between the Park2 knockout mice may be 
attributable to differences between the genetic background of the mouse strains used 
(discussed in (Perez and Palmiter, 2005)). The majority of studies used mice of variable 
mixed backgrounds. Isogenic strains are preferred when investigating the effect of gene 
knockout as genetic similarity tends to result in phenotypic uniformity, increasing the 
power to identify significant effects. It would be an advantage when comparing traits 
between different knockout mice for them to be on the same isogenic background, 
particularly if the genetic effect is modest, as appears to be the case of parkin. Therefore, until 
these carefully controlled studies are undertaken, it remains difficult to determine which of 
the identified phenotypic features are likely to be attributable to parkin.  
Isogenic strains may also be a hindrance if pathogenicity has undefined multigenic 
influences, as potentially could be the case for parkin. During the process of generating an 
inbred strain, mice undergo a process called inbreeding depression. In this process the 
reproductive fitness reduces as homozygosity increases because repressive alleles are 
unmasked. Therefore, founders of an inbred strain and their offspring must be considered 
selective survivors of the inbreeding process, and as such have a level of fitness that does 
not reflect the species as a whole (McClearn and McCarter, 2011). In a multifaceted disease 
such as PD, other genetic factors may contribute to disease progression. Therefore, the 
isogenic inbred strains could limit the affect of Park2 knockout. However, the negative 
effects associated with inbreeding depression can be overcome by generating F1 hybrids of 
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two different inbred strains. In the context of the Park2 knockout models, it may be 
noteworthy that the only strain that demonstrates significant loss of dopaminergic neurons 
in the substantia nigra, the Park2tm1Roo knockout mouse, was reported in a mixed 
129S2/C57BL6 (50/50) genetic background.  
Another factor that could be significant in the development of a disease phenotype is the 
environmental differences between laboratory mice and humans. It is clear that 
environmental factors influence PD development, and in some cases may cause PD. 
Laboratory mice are housed in controlled environments, often pathogen free, with none or 
limited exposure to environmental toxins or stresses. Therefore these mice may not be 
exposed to the appropriate triggers that are necessary for dopaminergic protective 
mechanisms to fail. Loss of parkin may result in a pre-degenerative state where neurons are 
under stress but not sufficiently compromised as to cause significant loss. Other cues, such 
as pro-inflammatory factors, could provide the additional stimulus required for 
degeneration to occur. This model may better explain an inherited autosomal recessive trait 
that takes multiple decades to manifest symptoms.  
The Park2 knockout mice are useful to understand the mechanistic consequence of loss of 
parkin function in a mammalian species. An improved understanding of the effect of parkin 
deletion on neuron and glial populations will provide considerable insight into the 
pathogenesis of PD, and the contribution that dopamine dysregulation plays in the 
pathogenic process. Cellular models have provided a great deal of information about the 
role of parkin in the turnover of protein and cellular constituents, in particular 
mitochondria, via the UPS and autophagy. The Park2 knockout models provide a 
sophisticated platform to refine and advance these studies, for example using neuronal and 
glial cultures derived from Park2 knockout mice. 
There are a number of avenues that can be explored to potentially develop a Park2 
knockout model with a pathological phenotype of clinical relevance. Crossing the Park2 
knockout mice with ǂ-synuclein, tau and ǃ-amyloid models has provided enormous 
insight into the role of parkin in the neurodegenerative process in vivo. Further research 
following on from these studies, including breeding to the conditional ǂ-synuclein 
knockin model currently in development (NIH project No. 1R21NS057795-01A1), has the 
potential to develop these mice into a more clinically relevant model. Likewise, the role of 
neuroinflammation in the neurodegenerative process could be further explored using 
Park2 knockout mice. This could be achieved by breeding to genetic models with 
perturbations in the inflammatory response or treatment with agents such as LPS. In 
addition, a second rodent model, knockout of parkin in the rat, has recently been 
developed (SAGE Labs). The phenotypic outcome will be of great interest to compare and 
contrast with the results already obtained in mouse models. 
4. Conclusion 
A quote by Michael FW Festing, an expert in the field of laboratory animal genetics, 
eloquently encapsulates the use of mouse models in disease research. “Models are subject to 
improvement through further research. A lot of animal research is aimed at understanding the animal 
as a potential model for particular human conditions, without being too precise as to what those 
conditions might be. Models are not just found. They need to be developed, and this requires an 
understanding of the biology of the species and the effects of various interventions such as 
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inactivating specific genes or manipulating the environment. As our understanding increases, so the 
chance of choosing the most appropriate models for a specific disease increases” (Festing, 2011). To 
date, seven Park2 knockout mice have been generated but Park2 knockout models still need 
to be developed in order to understand the clinical manifestation of parkin-mediated PD and 
the contribution of parkin to idiopathic PD. 
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Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra.
Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main
obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms
that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of
proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis. Previously
implicated culprits in PD neurodegeneration, mitochondrial dysfunction, and oxidative stress may also act in
part by causing the accumulation of misfolded proteins, in addition to producing other deleterious events in
dopaminergic neurons. Neurotoxin-based models have been important in elucidating the molecular cascade of
cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable
in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic
neurons to the degenerative process.
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